## Supplementary Material

# Galectin-9 alleviates LPS-induced preeclampsia-like impairment in rats via switching decidual macrophage polarization to M2 subtype

# Zhi-Hui Li<sup>1†</sup>, Li-Ling Wang<sup>1†</sup>, Hong Liu<sup>1</sup>, Kahinho P. Muyayalo<sup>1</sup>, Xiao-Bo Huang<sup>1</sup>, Gil Mor<sup>1,2</sup>, Ai-Hua Liao<sup>1\*</sup>

<sup>1</sup> Family Planning Research Institute, Center for Reproductive Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, <sup>2</sup> Reproductive Immunology Unit, Department of Obstetrics Gynecology and Reproductive Science, Yale University School of Medicine, New Haven, CT, United States

\* Correspondence: Ai-Hua Liao, MD, PhD: E-mail:aihua\_liao@sina.com

<sup>†</sup>These authors contributed equally to this work.

# 1 Supplementary Tables

#### Table S1

Antibodies used for immunohistochemistry (IHC), immunofluorescence (IF) and western blot (WB)

Antibody	Host	Dilution	Manufacturer	Cat#
anti-Cytokeratin 7 [EPR17078] (CK7)	Rabbit mAb	1:200	abcam, UK	ab181598
anti-alpha smooth muscle actin ( $\alpha$ -SMA)	Goat pAb	1:200	abcam, UK	ab21027
anti-Laminin antibody	Rabbit pAb	1:200	abcam, UK	ab11575
anti-CD68 [ED1]	Mouse mAb	1:200	abcam, UK	ab31630
CCR7 antibody	Goat pAb	1:50	Novus, USA	NB 100-712
anti-liver Arginase antibody(Arg1)	Goat pAb	1:50	abcam, UK	ab60176
anti-Tim 3 antibody	Rabbit pAb	1:100	abcam, UK	ab185703
anti-Gal-9 antibody	Rabbit pAb	1:100	abcam, UK	ab69630
DyLight 488 AffiniPure Goat anti-Mouse IgG(H+L)	Goat pAb	1:200	abcam, UK	A23210
DyLight 594 AffiniPure Goat anti-Rabbit IgG(H+L)	Goat pAb	1:200	Abbkine, China	A23420
Donkey Anti-Rabbit IgG H&L (Alexa Fluor® 594)	Donkey pAb	1:500	abcam, UK	ab150076
Donkey Anti-Goat IgG H&L (Alexa Fluor® 488)	Donkey pAb	1:500	abcam, UK	ab150129
β-actin(C4)	Mouse mAb	1:2000	Santa Cruz, USA	sc-4778
goat anti-rabbit IgG-HRP	Goat pAb	1:1000	Santa Cruz, USA	sc-2004
donkey anti-goat IgG-HRP	Donkey pAb	1:1000	Santa Cruz, USA	sc-2020
anti-mouse IgG-HRP	Goat	1:1000	PTG, USA	SA00001-1

### Table S2

Primer sequences for quantitative real-time PCR

Target	Forward primer	Reverse primer
β-actin	CTGAACCCTAAGGCCAACCG	GACCAGAGGCATACAGGGACAA
Arg1	TATCGGAGCGCCTTTCTCTA	ACAGACCGTGGGTTCTTCAC
iNOS	TCCTCAGGCTTGGGTCTTGTTAG	TTCAGGTCACCTTGGTAGGATTTG
IL-10	GAGAGAAGCTGAAGACCCTCTG	TCATTCATGGCCTTGTAGACAC
TGF-β	GGCACCATCCATGACATGAACCG	GCCGTACACAGCAGTTCTTCTCTG
TNF-α	GCCTCTTCTCATTCCTGCTC	CCCATTTGGGAACTTCTCCT
IL-1β	ATCTCACAGCAGCATCTCGACAAG	CACACTAGCAGGTCGTCATCATCC

### Table S3

Embryonic Day (E)	saline group (n=7)	LPS group (n=7)	LPS + Gal-9 group (n=5)
0	99.11±0.38	96.83±0.35	97.93±0.62
3	$100.42 \pm 0.32$	98.53±0.33	101.81±0.93
6	101.56±0.37	119.95±1.38 **	126.19±1.05 <b>▲</b>
8	102.26±0.91	120.57±1.17 <b>**</b>	109.02±0.87
10	101.56±0.73	123.71±0.78 <b>**</b>	104.99±1.79
12	101.99±0.69	123.44±0.38 <b>##</b>	102.90±0.44
14	102.82±0.69	126.00±0.68 <b>##</b>	103.92±0.80
16	101.28±0.49	121.61±0.56 <b>**</b>	101.51±0.48
18	99.98±0.43	125.73±0.61 <b>**</b>	102.06±0.64

SBP profiles (mmHg) in different groups

24h urinary protein level (mg/24h) in different groups

Embryonic Day (E)	saline group (n=7)	LPS group (n=7)	LPS + Gal-9 group (n=5)
0	$2.23 \pm 0.08$	2.25±0.05	2.11±0.04
3	2.16±0.03	2.30±0.05	2.39±0.05
6	$2.72 \pm 0.62$	4.13±0.04 <b>**</b>	4.29±0.07▲
9	2.37±0.06	4.57±0.06 <b>##</b>	3.02±0.09
12	2.41±0.04	4.55±0.06 <b>##</b>	3.19±0.08
15	$2.49 \pm 0.08$	5.49±0.05 <b>##</b>	2.64±0.04
18	2.76±0.06	5.78±0.03 <b>##</b>	2.85±0.04

#### Table S5

Fetal length (cm) and wet fetal wet weights (g) in different groups

Embryonic Day (E)	saline group (n=7)	LPS group (n=7)	LPS + Gal-9 group (n=5)
Fetal length (cm)	4.31±0.05	3.20±0.03 <b>**</b>	4.05±0.03
Fetal Weight (g)	4.61±0.06	3.07±0.04 <b>**</b> ##	4.20±0.06

\*\*p < 0.01 LPS vs. saline pregnancy group at E20;

<sup>##</sup>p < 0.01 LPS vs. LPS+Gal9 group at E20.

#### 2 Supplementary Figures



**Supplementary Figure 1.** Mean SBP and 24 h urinary protein in non-pregnancy group. Noted that significant increase of SBP and albuminuria was not observed in non-pregnant rats.

7



Supplementary Figure 2. Negative control images for the primary antibodies used in this study. (A) Negative control images for CK7 and α-SMA defaulted, only secondary antibodies of DyLight 488/594 were added. Bar = 500µm. (B) Negative control images for CD68, CCR7, Arg1 and Tim-3 defaulted, only secondary antibodies of Alexa Fluor 488/594 were added. Bar =  $100 \mu m$ .



**Supplementary Figure 3.** Western blots of the entire original PVDF for CD68, CCR7 and Arg1 in the decidua in different groups. Detected the molecule repeatedly in one experiment and three independent experiments totally.



**Supplementary Figure 4.** Western blots of the entire original PVDF for Tim-3 and  $\beta$ -actin in the decidua in different groups. Detected the molecule repeatedly in one experiment and three independent experiments totally.



**Supplementary Figure 5.** Western blots of the entire original PVDF for Gal-9 and  $\beta$ -actin in the decidua in different groups.

#### Supplementary Material



Supplementary Figure 6. Immunohistochemistry for Gal-9 in non-pregnancy groups. Noted that the expression of Gal-9 in non-pregnancy rat uteri was mainly localized on endometrial and glandular epithelium. The right panels are the negative controls. Bar =  $100\mu$ m.